Get the Stockscreener App
31.63
9.48%
2.74
Vera Therapeutics Inc stock is traded at $31.63, with a volume of 5.87M.
It is up +9.48% in the last 24 hours and down -26.66% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$28.89
Open:
$31.29
24h Volume:
5.87M
Relative Volume:
3.20
Market Cap:
$2.28B
Revenue:
-
Net Income/Loss:
$-368.95M
P/E Ratio:
-5.7039
EPS:
-5.5453
Net Cash Flow:
$-293.81M
1W Performance:
-3.83%
1M Performance:
-26.66%
6M Performance:
-25.08%
1Y Performance:
+48.71%
1-Day Range:
$29.73
$32.31
1-Week Range:
$28.86
$32.96
52-Week Range:
$21.15
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
31.63 | 2.16B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics Stock (VERA) Opinions on Positive eGFR Data Release - quiverquant.com
Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves - TechStock²
Vera Therapeutics Climbs as Investors React to TRUTAKNA Launch Progress and Near-Term IgAN Milestones - quiverquant.com
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics - Stock Titan
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's Why - MarketBeat
HC Wainwright Has Positive Estimate for VERA Q3 Earnings - MarketBeat
Vera stock rises on FDA review for kidney drug (VERA:NASDAQ) - Seeking Alpha
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA? - Sahm
(VERA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock - Investing.com
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock - Investing.com
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock - Investing.com
Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise - Stock Titan
Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan - Stock Titan
Goldman Sachs lowers Vera Therapeutics stock price target to $80 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts Vera Therapeutics stock price target on competition By Investing.com - Investing.com Nigeria
Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright cuts Vera Therapeutics stock price target on competition - Investing.com India
E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics, Inc. Stock 12‑Month Price Target Cut to $81.21, Implies 157% Upside - TradingView
Wedbush Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $34.00 - MarketBeat
Vera Therapeutics (VERA) Stock Analysis: A Biotech With Potential 157.85% Upside - DirectorsTalk Interviews
Vera Therapeutics (VERA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
VERA SWOT Analysis: Accelerated Approval of TRUTAKNA Marks a Key Milestone - GuruFocus
Vera Therapeutics Q2 Results: Net loss widens to $109.5 million - scanx.trade
Vera Therapeutics Q2 Results: EPS beats estimates despite wider losses - scanx.trade
Vera Therapeutics Q2 loss widens less than expected - TradingView
Vera Therapeutics (NASDAQ:VERA) Announces Quarterly Earnings Results - MarketBeat
Vera Therapeutics reports Q2 net loss of $109.5M as TRUTAKNA receives FDA accelerated approval - TradingView
Vera Therapeutics (VERA) ramps spending ahead of TRUTAKNA launch and posts $230.5M loss - Stock Titan
Vera's TRUTAKNA Gets FDA Accelerated Approval for IgA Nephropathy - Stock Titan
Dimensional Fund Advisors LP Decreases Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics (VERA) Earnings Date and Reports 2026 - MarketBeat
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
State Street Corporation (VERA) discloses 4.1M-share stake in Vera Therapeutics - Stock Titan
Vera Therapeutics grants equity inducement awards to new hires - scanx.trade
The Manufacturers Life Insurance Company Cuts Stock Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer - Stock Titan
Vera Therapeutics under pressure in first earnings since approval By Investing.com - Investing.com Canada
Vera Therapeutics names Nancy Lee Boman as chief regulatory officer in initial beneficial ownership filing - Bitget
Vera Therapeutics, Inc. (VERA) Stock Analysis: A Biotech With 153% Potential Upside - directorstalkinterviews.com
Vera Therapeutics (NASDAQ:VERA) Stock Price Down 5.8%Here's Why - MarketBeat
Price-Driven Insight from (VERA) for Rule-Based Strategy - Stock Traders Daily
BlackRock (NYSE: BLK) discloses 5.34M-share Vera Therapeutics (VERA) stake - Stock Titan
Vera Therapeutics (VERA) Expected to Announce Earnings on Tuesday - MarketBeat
Vera Therapeutics Inc (VERA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vera Therapeutics Inc (VERA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vera Therapeutics Inc (VERA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vera Therapeutics Inc (VERA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vera Therapeutics Inc (VERA) Balance Sheet - TradingKey
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):